The SORENTO study enrolment has exceeded the target of 302 randomized participants across 103 clinical sites in 12 countries in North America, Europe, Asia and Australia. The primary endpoint is to demonstrate statistically significant increased progression-free survival of treatment with CAM2029 compared to standard of care in patients with metastatic, unresectable GEP-NET. Topline study results will be read out after 194 confirmed tumour progression events or deaths.
“SORENTO is the largest randomized clinical study of a somatostatin receptor ligand in GEP-NET performed to date. The rapid rate of patient enrolment reflects a high interest in CAM2029 and the SORENTO study within the global NET treating community”, says coordinating investigator for the study Dr Simron Singh, Medical oncologist at the Susan Leslie Clinic for neuroendocrine cancers, Odette Cancer Center, Sunnybrook Health Sciences center, Toronto, Canada, associate professor at the University of Toronto. “Alongside assessment of the primary endpoint of significantly improved Tumor control, self-administration of CAM2029 is evaluated in SORENTO as part of the global movement to increase patient empowerment and patient centered care.”
